title: Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.
abstract: Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell disorders. While some MPN patients have an indolent course, all are at risk of progressing to severe marrow failure or transforming into acute leukemia. Allogeneic hematopoietic cell transplantation (allo-HCT) is the only potential curative therapy. Major pre-transplant risk factors are disease stage of the MPN, the presence of comorbid conditions and the use of HLA non-identical donors. The development of reduced-intensity conditioning regimens has allowed for successful allo-HCT even for older patients and patients with comorbid conditions. The pre-transplant use of JAK2 inhibitors, which may be effective in down staging a patient's disease, may improve the outcomes following allo-HCT.
authors.affiliation: Clinical Research Division, Cord Blood Transplant Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; University of Washington Medical Center, Seattle, WA 98195, USA.
authors.forename: Rachel B
authors.initials: RB
authors.lastname: Salit
authors.affiliation: Clinical Research Division, Cord Blood Transplant Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; University of Washington Medical Center, Seattle, WA 98195, USA. Electronic address: jdeeg@fhcrc.org.
authors.forename: H Joachim
authors.initials: HJ
authors.lastname: Deeg
mesh_terms: D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors; D009196:Myeloproliferative Disorders / Q000201:enzymology / Q000628:therapy*; D009570:Nitriles; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053614:Janus Kinase 2
keywords: Essential thrombocythemia; Hematopoietic stem cell transplantation; Myelofibrosis; Myeloproliferative neoplasms (MPN); Polycythemia vera; Ruxolitinib